BLOOD 2023: Cilta-Cel Has Potential for Multiple Myeloma After First Relapse
74 percent reduction in progression and death seen in phase 3 trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
74 percent reduction in progression and death seen in phase 3 trial
Only registered members have full access to PracticeUpdate content.